Objective To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …

Objective We aimed to perform a meta-analysis of randomized controlled trials (RCTs) to
summarize the overall effect of tocilizumab on the risk of mortality among patients with …

Materials and methods Online databases (PubMed and Cochrane) were searched until
June 29, 2020, for original articles investigating the immunological response in COVID-19 …

Tocilizumab, an anti-interleukin-6 receptor, administrated during the right timeframe may be
beneficial against coronavirus-disease-2019 (COVID-19) pneumonia. All patients admitted …

Tocilizumab is an interleukin receptor inhibitor that has been used in patients with COVID-19
pneumonia. There are recent randomized controlled trials (RCTs) that evaluated the efficacy …

Objectives Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …

Objectives Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …

Objectives The purpose of this study is to evaluate clinical outcomes in patients with critical
COVID-19 pneumonia requiring invasive mechanical ventilation who were treated with …

Aims Tocilizumab has emerged as an important therapy in treating patients with coronavirus
disease (COVID‐19). Our purpose was to evaluate the efficacy and safety of tocilizumab …

Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to
assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and …